CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-04-04 DOI:10.1080/2162402x.2024.2338965

Ayush Pant, Brandon Hwa-Lin Bergsneider, Siddhartha Srivastava, Timothy Kim, Aanchal Jain, Sadhana Bom, Pavan Shah, Nivedha Kannapadi, Kisha Patel, John Choi, Kwang Bog Cho, Rohit Verma, Caren Yu-Ju Wu, Henry Brem, Betty Tyler, Drew M. Pardoll, Christina Jackson, Michael Lim

引用次数: 0

Abstract

Immunotherapy has revolutionized the treatment of cancers. Reinvigorating lymphocytes with checkpoint blockade has become a cornerstone of immunotherapy for multiple tumor types, but the treatment ...

查看原文本刊更多论文

CCR2和CCR5联合抑制可调节胶质瘤的免疫抑制性髓系环境，并与抗PD-1疗法协同增效

免疫疗法为癌症治疗带来了革命性的变化。通过检查点阻断重振淋巴细胞已成为多种肿瘤类型免疫疗法的基石，但治疗...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.